Cargando…

Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence

Asthma is the commonest chronic disease affecting airways in humans and has an increasing global disease burden. Inhaled corticosteroids (ICS) are the first-line therapeutic option for asthma, and addition of a long-acting beta 2-agonist (LABA) has been shown to improve asthma control. A combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajesh, V., Augustine, Jolsana, Divya, R., Cleetus, Melcy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509561/
https://www.ncbi.nlm.nih.gov/pubmed/33005277
http://dx.doi.org/10.1155/2020/8631316
_version_ 1783585623589781504
author Rajesh, V.
Augustine, Jolsana
Divya, R.
Cleetus, Melcy
author_facet Rajesh, V.
Augustine, Jolsana
Divya, R.
Cleetus, Melcy
author_sort Rajesh, V.
collection PubMed
description Asthma is the commonest chronic disease affecting airways in humans and has an increasing global disease burden. Inhaled corticosteroids (ICS) are the first-line therapeutic option for asthma, and addition of a long-acting beta 2-agonist (LABA) has been shown to improve asthma control. A combination of the two agents in a single inhaler is beneficial with regard to ease of administration and patient compliance. Various ICS-LABA formulations are available across various countries in the world, one among them being formoterol-fluticasone. Both formoterol and fluticasone have pharmacologic peculiarities which places the combination in a uniquely advantageous position when it comes to asthma therapy. The present review focuses on some of the, hitherto, less explored aspects of this combination inhaler such as real-world efficacy, impact on budget allocation, results of switch-over therapy, and potential to improve adherence to asthma treatment. It also provides practical recommendations on positioning it in real-world asthma management.
format Online
Article
Text
id pubmed-7509561
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-75095612020-09-30 Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence Rajesh, V. Augustine, Jolsana Divya, R. Cleetus, Melcy Can Respir J Review Article Asthma is the commonest chronic disease affecting airways in humans and has an increasing global disease burden. Inhaled corticosteroids (ICS) are the first-line therapeutic option for asthma, and addition of a long-acting beta 2-agonist (LABA) has been shown to improve asthma control. A combination of the two agents in a single inhaler is beneficial with regard to ease of administration and patient compliance. Various ICS-LABA formulations are available across various countries in the world, one among them being formoterol-fluticasone. Both formoterol and fluticasone have pharmacologic peculiarities which places the combination in a uniquely advantageous position when it comes to asthma therapy. The present review focuses on some of the, hitherto, less explored aspects of this combination inhaler such as real-world efficacy, impact on budget allocation, results of switch-over therapy, and potential to improve adherence to asthma treatment. It also provides practical recommendations on positioning it in real-world asthma management. Hindawi 2020-09-14 /pmc/articles/PMC7509561/ /pubmed/33005277 http://dx.doi.org/10.1155/2020/8631316 Text en Copyright © 2020 V. Rajesh et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Rajesh, V.
Augustine, Jolsana
Divya, R.
Cleetus, Melcy
Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence
title Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence
title_full Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence
title_fullStr Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence
title_full_unstemmed Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence
title_short Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence
title_sort inhaled formoterol-fluticasone single inhaler therapy in asthma: real-world efficacy, budget impact, and potential to improve adherence
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509561/
https://www.ncbi.nlm.nih.gov/pubmed/33005277
http://dx.doi.org/10.1155/2020/8631316
work_keys_str_mv AT rajeshv inhaledformoterolfluticasonesingleinhalertherapyinasthmarealworldefficacybudgetimpactandpotentialtoimproveadherence
AT augustinejolsana inhaledformoterolfluticasonesingleinhalertherapyinasthmarealworldefficacybudgetimpactandpotentialtoimproveadherence
AT divyar inhaledformoterolfluticasonesingleinhalertherapyinasthmarealworldefficacybudgetimpactandpotentialtoimproveadherence
AT cleetusmelcy inhaledformoterolfluticasonesingleinhalertherapyinasthmarealworldefficacybudgetimpactandpotentialtoimproveadherence